12:00 AM
Jan 02, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Xgeva denosumab regulatory update

FDA's Oncologic Drugs Advisory Committee will meet on Feb. 8 to discuss an sBLA from Amgen for Xgeva denosumab to prevent bone metastases in men with castration-resistant prostate cancer (CRPC). The PDUFA...

Read the full 138 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >